Antidepressant Medicine Use and Risk of Developing Diabetes During the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study by Rubin, Richard R. et al.
Antidepressant Medicine Use and Risk of
Developing Diabetes During the Diabetes
Prevention Program and Diabetes
Prevention Program Outcomes Study
RICHARD R. RUBIN, PHD1,2
YONG MA, MS3
MARK PEYROT, PHD1,4
DAVID G. MARRERO, PHD5
DAVID W. PRICE, MD6,7
ELIZABETH BARRETT-CONNOR, MD8
WILLIAM C. KNOWLER, MD, DRPH9
FOR THE DIABETES PREVENTION PROGRAM
RESEARCH GROUP*
OBJECTIVE— To assess the association between antidepressant medicine use and risk of
developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention
Program Outcomes Study (DPPOS).
RESEARCH DESIGN AND METHODS— DPP/DPPOS participants were assessed for
diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months
in DPPOS for a median 10.0-year follow-up.
RESULTS— Controlled for factors associated with diabetes risk, continuous antidepressant
use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio
2.34 [95% CI 1.32–4.15]) and lifestyle (2.48 [1.45–4.22]) arms, but not in the metformin arm
(0.55 [0.25–1.19]).
CONCLUSIONS— Continuous antidepressant use was significantly associated with diabe-
tes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account
for this association, which could represent a drug effect or reflect differences not assessed in this
study between antidepressant users and nonusers.
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Our earlier report from the DiabetesPrevention Program (DPP) (1) wasthe first to examine antidepressant
medicine (ADM)-related diabetes risk in
an overweight population with elevated
fasting glucose and impaired glucose tol-
erance. We found in the placebo and life-
style arms that when other factors
associated with diabetes risk (age, sex, ed-
ucation, fasting plasma glucose at base-
line, weight at baseline, weight change
during the study, and depression symp-
toms at baseline and during the study)
were controlled, baseline ADM use and
continuous ADM use during the study
(compared with no use) were associated
with significantly increased diabetes risk;
in the lifestyle arm, intermittent ADM use
during the study was also associated with
increased diabetes risk. Among met-
formin arm participants, ADM use was
not associated with developing diabetes.
The present study extends the dura-
tion of follow-up in our previous report
by including 7 years of the Diabetes
Prevention Program Outcomes Study
(DPPOS) and providing a median 10.0-
year (interquartile range 9.0–10.5) fol-
low-up since randomization to the DPP.
RESEARCH DESIGN AND
METHODS— Participants (N  3,234)
at high risk for developing type 2 diabetes
were randomized to the DPP between
1996 and 1999. Characteristics of the
study population are reported else-
where (1).
In July 2001, masked DPP treatment
was discontinued after it was established
that lifestyle intervention reduced inci-
dence of diabetes by 58% and metformin
by 31% compared with placebo (2).
All 3,150 surviving DPP participants
who had not withdrawn consent were el-
igible for the DPPOS, and 2,665 enrolled.
Institutional review boards approved all
DPP and DPPOS protocols and informed
consent procedures. Participants signed
written consent forms after discussion of
all aspects of the studies with study
staff (3).
DPP/DPPOS participants brought all
prescription medicines, including ADMs,
to clinic visits. Study staff identified all
ADMs by generic name, brand name, or
both.
Diabetes was diagnosed based on an
annual oral glucose tolerance test or a
semiannual fasting plasma glucose test. A
confirmation test was required, usually
within 6 weeks (1). Fasting insulin was
measured at annual visits with the oral
glucose tolerance test (2).
Statistical analysis
ADM use was reported quarterly during
the DPP and every 6 months during the
DPPOS. Cox proportional hazard models
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(1) were used to evaluate whether taking
ADMs was associated with developing
diabetes.
ADM use was defined as a time-
dependent categorical variable up to each
time point evaluated with three levels:
never used, used intermittently (at least
once but not always), and used continu-
ously (at all visits). At each successive
time point, the value of the variable was
calculated based on all previous time
points, including the current measure-
ment. A significant interaction between
ADM use and treatment groups was de-
tected, and we modeled the association
separately for each treatment group.
Time-dependent covariate analyses
(1) were used to model the above covari-
ates and diabetes risk with adjustment for
factors associated with an increased risk
of developing diabetes (race/ethnicity,
age, sex, education, fasting plasma glu-
cose at baseline, weight at baseline, and
weight change during the study). These
risks are reported as adjusted hazard ra-
tios (HRas).
We now present data over a median
of 10 years since randomization, includ-
ing the time period of the first phase of the
DPP that was reported previously (1).
Therefore, these analyses are not inde-
pendent of the previous study and should
be considered an extension, not a replica-
tion, of those findings. All analyses were
performed using SAS (SAS Institute,
Cary, NC).
RESULTS— When other factors asso-
ciated with an increased risk of develop-
ing diabetes were controlled, continuous
ADM use during the DPP/DPPOS (com-
pared with no use) was strongly associ-
ated with diabetes risk (Fig. 1) for
participants in the placebo (HRa 2.34
[95% CI 1.32–4.15] and lifestyle (2.48
[1.45–4.22]) arms. In the placebo arm,
the association between intermittent
ADM use and diabetes trended toward
statistical significance (1.34 [0.99 –
1.81]). In the metformin arm, ADM use
was not associated with diabetes risk
(0.55 [0.25–1.19]). There was a signifi-
cant difference between the lifestyle and
metformin arms in the association be-
tween ADM and diabetes risk. Results did
not change when we excluded partici-
pants taking ADMs that are more likely to
cause weight gain (tricyclic and tetracy-
clic agents).
CONCLUSIONS— The current find-
ings extend those of our earlier report (1),
although over the longer follow-up in this
study that includes the DPPOS, we did
not find an association with intermittent
ADM use and diabetes risk in the lifestyle
arm. These findings are similar to those in
a previous report that long-term use of
ADM increased the risk of developing di-
abetes (4). Other studies (5,6), have also
reported increased ADM-related diabetes
risk.
The association between ADM use
and diabetes risk remained significant
when likely mediators of this association
were controlled. This association could
represent a medication effect, or it could
reflect differences not assessed in the
study between ADM and non-ADM users.
ADM use was not associated with diabetes
risk in the metformin arm. Although there
is no obvious explanation for this latter
finding, one study found that metformin
induces the release of 5-hydroxytrypta-
mine through neuronal and nonneuronal
mechanisms and thus increases insulin
secretion (7). Metformin also appears to
ameliorate inflammation (8), and inflam-
matory markers appear to be associated
with depression (9).
Strengths and limitations
Strengths of the current study include the
large, racially and ethnically diverse pop-
ulation, the definitive assessment of glu-
cose tolerance and diabetes, repeated
collection of data on both ADM use and
depression symptoms, and repeated as-
sessment of metabolic diabetes risk fac-
tors. We were also able to more accurately
determine the onset of diabetes—a con-
siderable advance over studies that rely
on clinical records that may not accu-
rately capture when diabetes actually
developed.
Potential DPP participants were ex-
cluded if they were taking bupropion or
any ADM in greater than the lowest ther-
apeutic dose, so the study sample was not
representative of the general population.
The absolute number of diabetes cases in
the continuous ADM group was quite
small (placebo n  18, lifestyle n  15).
During the DPP/DPPOS we did not collect
data on ADM dosage, so we could not
examine the association between dosage
and diabetes risk.
Implications
Further study of ADM-related diabetes
risk has substantial public health implica-
tions. The possible benefits of metformin
in depression treatment should also be
studied.
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Figure 1—For each treatment group, from left to right, the three bars represent no exposure, intermittent exposure, and continuous exposure. The
error bars represent 95% CIs for the point estimates.
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